| Q82385466 | 2α-Methyl-19-nor-(20S)-1,25-dihydroxyvitamin D(3) protects the insulin 2 knockout non-obese diabetic mouse from developing type 1 diabetes without hypercalcaemia |
| Q36376640 | A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice |
| Q34341601 | A recombination hotspot leads to sequence variability within a novel gene (AK005651) and contributes to type 1 diabetes susceptibility |
| Q35605732 | Aberrancies in antigen-presenting cells and T cells in autoimmune thyroid disease. A role in faulty tolerance induction |
| Q28512196 | Absence of a reductase, NCB5OR, causes insulin-deficient diabetes |
| Q44137350 | Active Subjects With Autoimmune Type 1 Diabetes Have Better Metabolic Profiles Than Sedentary Controls |
| Q34182038 | Acute response of peripheral blood cell to autologous hematopoietic stem cell transplantation in type 1 diabetic patient |
| Q33950195 | Adeno-associated virus vector-mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice |
| Q27008307 | Advancing animal models of human type 1 diabetes by engraftment of functional human tissues in immunodeficient mice |
| Q39711541 | Age-related deregulation of Aire and peripheral tissue antigen genes in the thymic stroma of non-obese diabetic (NOD) mice is associated with autoimmune type 1 diabetes mellitus (DM-1). |
| Q33869564 | Alcohol facilitates CD1d loading, subsequent activation of NKT cells, and reduces the incidence of diabetes in NOD mice |
| Q34546776 | Alteration of intra-pancreatic target-organ specificity by abrogation of Aire in NOD mice |
| Q35196943 | Altered expression of somatostatin receptors in pancreatic islets from NOD mice cultured at different glucose concentrations in vitro and in islets transplanted to diabetic NOD mice in vivo |
| Q42445681 | Altered monocyte cyclo-oxygenase response in non-obese diabetic mice |
| Q35920996 | Animal models have little to teach us about type 1 diabetes: 1. In support of this proposal |
| Q35926919 | Animal models have little to teach us about type 1 diabetes: 2. In opposition to this proposal |
| Q36423648 | Animal models of diabetic uropathy. |
| Q38660322 | Animal models of human type 1 diabetes for evaluating combination therapies and successful translation to the patient with type 1 diabetes. |
| Q34182775 | Anti-idiotypic antibody specific to GAD65 autoantibody prevents type 1 diabetes in the NOD mouse |
| Q87413637 | Antibody combination therapy targeting CD25, CD70 and CD8 reduces islet inflammation and improves glycaemia in diabetic mice |
| Q34567725 | Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire? |
| Q37051562 | Antigen-specific tolerogenic and immunomodulatory strategies for the treatment of autoimmune arthritis |
| Q36766166 | Are insights gained from NOD mice sufficient to guide clinical translation? Another inconvenient truth |
| Q36805072 | Assessment of gastric emptying in non-obese diabetic mice using a [13C]-octanoic acid breath test |
| Q38034269 | At the crossroad of T cells, adipose tissue, and diabetes |
| Q54396931 | Attenuation of allergy to ovomucoid in pigs by neonatal treatment with heat-killed Escherichia coli or E. coli producing porcine IFN-gamma. |
| Q34113929 | Autoantigens plus interleukin-10 suppress diabetes autoimmunity |
| Q38358439 | Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive. |
| Q24647362 | Autologous umbilical cord blood infusion for type 1 diabetes |
| Q92447451 | BTNL2-Ig Protein Attenuates Type 1 Diabetes in Non-Obese Diabetic (NOD) Mice |
| Q27312395 | Bioluminescence imaging reveals dynamics of beta cell loss in the non-obese diabetic (NOD) mouse model |
| Q38106720 | Bone marrow stem cell as a potential treatment for diabetes |
| Q44347477 | CD8+ regulatory T cells are responsible for GAD-IgG gene-transferred tolerance induction in NOD mice |
| Q36399304 | CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice |
| Q36501954 | Cannabidiol arrests onset of autoimmune diabetes in NOD mice |
| Q35793015 | Catenarin Prevents Type 1 Diabetes in Nonobese Diabetic Mice via Inhibition of Leukocyte Migration Involving the MEK6/p38 and MEK7/JNK Pathways |
| Q33705115 | Cathepsin L Inhibition Prevents Murine Autoimmune Diabetes via Suppression of CD8+ T Cell Activity |
| Q40156885 | Comparative therapeutic effects of orally administered 1,25-dihydroxyvitamin D(3) and 1alpha-hydroxyvitamin D(3) on type-1 diabetes in non-obese diabetic mice fed a normal-calcaemic diet |
| Q35852428 | Comprehensive Survey of miRNA-mRNA Interactions Reveals That Ccr7 and Cd247 (CD3 zeta) are Posttranscriptionally Controlled in Pancreas Infiltrating T Lymphocytes of Non-Obese Diabetic (NOD) Mice |
| Q55083872 | Contrast-enhanced ultrasound measurement of pancreatic blood flow dynamics predicts type 1 diabetes progression in preclinical models. |
| Q56902182 | Costimulation and autoimmune diabetes in BB rats |
| Q40497673 | Coxsackievirus B3 infection and type 1 diabetes development in NOD mice: insulitis determines susceptibility of pancreatic islets to virus infection |
| Q37557466 | Coxsackievirus B4 and type 1 diabetes pathogenesis: contribution of animal models |
| Q42200757 | Coxsackievirus can persist in murine pancreas by deletion of 5' terminal genomic sequences |
| Q44325323 | Coxsackievirus immunization delays onset of diabetes in non-obese diabetic mice |
| Q36766161 | Coxsackievirus infections and NOD mice: relevant models of protection from, and induction of, type 1 diabetes |
| Q47626694 | Current practices and future outlook on the integration of biomarkers in the drug development process |
| Q35116303 | Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same? |
| Q26799371 | Current status and patent prospective of animal models in diabetic research |
| Q35405027 | Deletion of the G6pc2 gene encoding the islet-specific glucose-6-phosphatase catalytic subunit-related protein does not affect the progression or incidence of type 1 diabetes in NOD/ShiLtJ mice |
| Q38059518 | Dendritic cell therapy for Type 1 diabetes suppression |
| Q53623250 | Deregulated stress system in non-obese diabetic lymphocyte. |
| Q34790078 | Detecting early-warning signals of type 1 diabetes and its leading biomolecular networks by dynamical network biomarkers |
| Q35851189 | Detection of glutamic acid decarboxylase-activated T cells with I-Ag7 tetramers |
| Q33508234 | Detection of molecular paths associated with insulitis and type 1 diabetes in non-obese diabetic mouse |
| Q37093206 | Developing tTA transgenic rats for inducible and reversible gene expression |
| Q50935737 | Development of a Mouse Model of Metabolic Syndrome, Pulmonary Hypertension, and Heart Failure with Preserved Ejection Fraction. |
| Q35622028 | Development of new strategies to prevent type 1 diabetes: the role of animal models. |
| Q35101430 | Development of type 1 diabetes mellitus in nonobese diabetic mice follows changes in thymocyte and peripheral T lymphocyte transcriptional activity |
| Q43115993 | Diabetes-associated dry eye syndrome in a new humanized transgenic model of type 1 diabetes |
| Q47234300 | Dietary gluten alters the balance of pro-inflammatory and anti-inflammatory cytokines in T cells of BALB/c mice |
| Q38340376 | Differential regulation of islet-specific glucose-6-phosphatase catalytic subunit-related protein gene transcription by Pax-6 and Pdx-1. |
| Q36225473 | Differentiation and transplantation of functional pancreatic beta cells generated from induced pluripotent stem cells derived from a type 1 diabetes mouse model. |
| Q36019487 | Discovery of Phosphorylated Peripherin as a Major Humoral Autoantigen in Type 1 Diabetes Mellitus. |
| Q34660693 | Diubiquitin (Ubd) is a susceptibility gene for virus-triggered autoimmune diabetes in rats |
| Q35946087 | Dll4-Notch signaling in Flt3-independent dendritic cell development and autoimmunity in mice |
| Q50882981 | ERK1 is dispensable for mouse pancreatic beta cell function but is necessary for glucose-induced full activation of MSK1 and CREB. |
| Q38382091 | Effect of maternal diabetes on the embryo, fetus, and children: congenital anomalies, genetic and epigenetic changes and developmental outcomes |
| Q38189119 | Effector and regulatory T cell subsets in diabetes-associated inflammation. Is there a connection with ST2/IL-33 axis? Perspective. |
| Q44655252 | Effects of streptozotocin on autoimmune diabetes in NOD mice |
| Q37163580 | Elimination of T cell reactivity to pancreatic β cells and partial preservation of β cell activity by peptide blockade of LFA-1:ICAM-1 interaction in the NOD mouse model |
| Q64230036 | Endogenous Pancreatic β Cell Regeneration: A Potential Strategy for the Recovery of β Cell Deficiency in Diabetes |
| Q47557792 | Endogenous Reprogramming of Alpha Cells into Beta Cells, Induced by Viral Gene Therapy, Reverses Autoimmune Diabetes. |
| Q96951726 | Engineering immunomodulatory biomaterials for type 1 diabetes |
| Q37668475 | Enteroviruses, type 1 diabetes and hygiene: a complex relationship |
| Q44814113 | European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes |
| Q34208736 | Evaluating preclinical efficacy |
| Q91691061 | Extracellular matrix and the maintenance and loss of peripheral immune tolerance in autoimmune insulitis |
| Q35024527 | Extreme genetic risk for type 1A diabetes |
| Q39740128 | Fatal attraction: chemokines and type 1 diabetes |
| Q34323684 | Forced IDO1 expression in dendritic cells restores immunoregulatory signalling in autoimmune diabetes |
| Q35122170 | Gene- and cell-based therapeutics for type I diabetes mellitus |
| Q35796924 | Generation of stable pluripotent stem cells from NOD mouse tail-tip fibroblasts |
| Q36570968 | Genetic ablation of lymphocytes and cytokine signaling in nonobese diabetic mice prevents diet-induced obesity and insulin resistance |
| Q44524587 | Genetic control of non obese diabetic mice susceptibility to high-dose streptozotocin-induced diabetes |
| Q35539009 | Genetic separation of the transplantation tolerance and autoimmune phenotypes in NOD mice |
| Q28215982 | Genetics of type 1 diabetes mellitus |
| Q30883833 | Genome-wide end-sequenced BAC resources for the NOD/MrkTac() and NOD/ShiLtJ() mouse genomes |
| Q36235501 | Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse |
| Q34072322 | Glucose homeostasis in pre-diabetic NOD and lymphocyte-deficient NOD/SCID mice during gestation |
| Q33894591 | Grafts of supplementary thymuses injected with allogeneic pancreatic islets protect nonobese diabetic mice against diabetes |
| Q34648219 | Group B coxsackievirus diabetogenic phenotype correlates with replication efficiency |
| Q34346057 | Growth of rotaviruses in primary pancreatic cells |
| Q44893510 | Guidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes |
| Q35578236 | Harnessing the Immunomodulatory Properties of Sertoli Cells to Enable Xenotransplantation in Type I Diabetes |
| Q37484889 | Heme oxygenase-1 protects interstitial cells of Cajal from oxidative stress and reverses diabetic gastroparesis. |
| Q37248995 | Homing of GAD65 specific autoimmunity and development of insulitis requires expression of both DQ8 and human GAD65 in transgenic mice. |
| Q33992348 | Hormonal regulation of physiological cell turnover and apoptosis |
| Q24656069 | Human T regulatory cell therapy: take a billion or so and call me in the morning |
| Q49566444 | Human amylin induces CD4+Foxp3+ regulatory T cells in the protection from autoimmune diabetes |
| Q44653755 | IA-2 is not required for the development of diabetes in NOD mice |
| Q38117368 | Immune Regulation in T1D and T2D: Prospective Role of Foxp3+ Treg Cells in Disease Pathogenesis and Treatment |
| Q36229062 | Immune assessments in developmental and juvenile toxicology: practical considerations for the regulatory safety testing of pharmaceuticals |
| Q34882557 | Immunologic and genetic factors in type 1 diabetes |
| Q34790085 | Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases |
| Q38102390 | Immunomodulatory molecules of Fasciola hepatica: candidates for both vaccine and immunotherapeutic development |
| Q36167431 | Immunomodulatory therapy of human type 1 diabetes: lessons from the mouse |
| Q33815506 | Immunotherapy of type 1 diabetes: where are we and where should we be going? |
| Q52430441 | Improved Murine MHC-Deficient HLA Transgenic NOD Mouse Models for Type 1 Diabetes Therapy Development. |
| Q36512327 | Induction of active tolerance and involvement of CD1d-restricted natural killer T cells in anti-CD3 F(ab')2 treatment-reversed new-onset diabetes in nonobese diabetic mice |
| Q34527126 | Induction of mixed chimerism with MHC-mismatched but not matched bone marrow transplants results in thymic deletion of host-type autoreactive T-cells in NOD mice |
| Q37682917 | Induction of oral tolerance to prevent diabetes with transgenic plants requires glutamic acid decarboxylase (GAD) and IL-4. |
| Q27334532 | Inhibition of Autoimmune Diabetes in NOD Mice by miRNA Therapy |
| Q36165620 | Inhibition of hyaluronan synthesis restores immune tolerance during autoimmune insulitis |
| Q44967038 | Inhibition of the proteasome reduces transfer-induced diabetes in nonobese diabetic mice |
| Q34520643 | Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes |
| Q33814945 | Insulin-dependent diabetes mellitus and its animal models. |
| Q34542675 | Insulin-like growth factor-1 stimulates regulatory T cells and suppresses autoimmune disease. |
| Q36249643 | Involvement of sulfatide in beta cells and type 1 and type 2 diabetes |
| Q46236719 | Iodine and tri-iodo-thyronine reduce the incidence of type 1 diabetes mellitus in the autoimmune prone BB rats |
| Q33869101 | Islet lymphocyte subsets in male and female NOD mice are qualitatively similar but quantitatively distinct. |
| Q34479316 | Islet-specific CTL cloned from a type 1 diabetes patient cause beta-cell destruction after engraftment into HLA-A2 transgenic NOD/scid/IL2RG null mice |
| Q51006250 | Islet/pancreas transplantation: challenges for pediatrics. |
| Q34638339 | Isomer-specific LC/MS and LC/MS/MS profiling of the mouse serum N-glycome revealing a number of novel sialylated N-glycans |
| Q98177245 | Lentiviral gene therapy vectors encoding VIP suppressed diabetes-related inflammation and augmented pancreatic beta-cell proliferation |
| Q36870085 | Leptin in autoimmunity: many questions, some answers |
| Q37110531 | Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes |
| Q33628140 | Limited effect of CpG ODN in preventing type 1 diabetes in NOD mice |
| Q36591024 | Longitudinal Frequencies of Blood Leukocyte Subpopulations Differ between NOD and NOR Mice but Do Not Predict Diabetes in NOD Mice |
| Q27008200 | Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity |
| Q34974382 | Lower frequency of CD62L(high) and higher frequency of TNFR2(+) Tregs are associated with inflammatory conditions in type 1 diabetic patients |
| Q36443938 | Lymphocytes with aberrant expression of Fas or Fas ligand attenuate immune bone marrow failure in a mouse model |
| Q34064185 | Metabolic regulation in progression to autoimmune diabetes |
| Q47735079 | Modelling diabetic nephropathy in mice. |
| Q35968974 | Moderate Intensity Training Impact on the Inflammatory Status and Glycemic Profiles in NOD Mice |
| Q59829524 | Modulation of diabetes in NOD mice by GAD65-specific monoclonal antibodies is epitope specific and accompanied by anti-idiotypic antibodies |
| Q42043629 | Molecular analysis of an echovirus 3 strain isolated from an individual concurrently with appearance of islet cell and IA-2 autoantibodies |
| Q34390741 | Molecular genetic analysis of diabetes in mice |
| Q33961022 | NOD mice are defective in proteasome production and activation of NF-kappaB |
| Q53634474 | NOD mice are functionally deficient in the capacity of cross-presentation. |
| Q35798168 | Natural killer T cells as targets for immunotherapy of autoimmune diseases |
| Q30843737 | Navigating diabetes-related immune epitope data: resources and tools provided by the Immune Epitope Database (IEDB) |
| Q35539035 | Neuronal elements in the pathogenesis of type 1 diabetes |
| Q36735358 | Neutralization of IL-4 and IFN-γ Facilitates inducing TGF-β-induced CD4(+)Foxp3(+) Regulatory Cells |
| Q34564255 | New therapeutic approaches to type 1 diabetes: from prevention to cellular or gene therapies |
| Q22306219 | Noncalcemic Actions of Vitamin D Receptor Ligands |
| Q30434071 | Nonobese diabetic (NOD) mice congenic for a targeted deletion of 12/15-lipoxygenase are protected from autoimmune diabetes |
| Q36370946 | Normal incidence of diabetes in NOD mice tolerant to glutamic acid decarboxylase |
| Q29393228 | Opinion: Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes |
| Q36640081 | Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells |
| Q59600053 | Overexpression of extracellular-SOD in islets of nonobese diabetic mice and development of diabetes |
| Q53531845 | Overexpression of the autoantigen IA-2 puts beta cells into a pre-apoptotic state: autoantigen-induced, but non-autoimmune-mediated, tissue destruction. |
| Q86967394 | PD-1-dependent restoration of self-tolerance in the NOD mouse model of diabetes after transient anti-TCRβ mAb therapy |
| Q36945852 | Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion |
| Q34605626 | Physiology and pathophysiology of the interstitial cells of Cajal: from bench to bedside. IV. Genetic and animal models of GI motility disorders caused by loss of interstitial cells of Cajal |
| Q81658222 | Porcine IgE in the context of experimental food allergy: purification and isotype-specific antibodies |
| Q37376932 | Potential for vitamin D receptor agonists in the treatment of cardiovascular disease |
| Q37626855 | Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes |
| Q34830048 | Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood |
| Q35107187 | Premature CD4+ T cell aging and its contribution to lymphopenia-induced proliferation of memory cells in autoimmune-prone non-obese diabetic mice |
| Q35976659 | Prevention of autoimmune diabetes by ectopic pancreatic β-cell expression of interleukin-35. |
| Q37532745 | Prevention of type 1 diabetes by gene therapy |
| Q35902878 | Prevention of type 1 diabetes in the rat with an allele-specific anti-T-cell receptor antibody: Vβ13 as a therapeutic target and biomarker |
| Q83168646 | Pro-apoptotic DNA vaccination ameliorates new onset of autoimmune diabetes in NOD mice and induces foxp3+ regulatory T cells in vitro |
| Q37821494 | Protection against or triggering of Type 1 diabetes? Different roles for viral infections |
| Q54471977 | Protection of non-obese diabetic mice from autoimmune diabetes by Escherichia coli heat-labile enterotoxin B subunit. |
| Q36344113 | Quantification of chemokines by real-time reverse transcriptase PCR: applications in type 1 diabetes |
| Q46465603 | Quantitative analysis of total serum glycome in human and mouse |
| Q42676935 | Questioning four preconceived ideas on immunotherapy of clinical type 1 diabetes: lessons from recent CD3 antibody trials |
| Q34387892 | RAG-dependent peripheral T cell receptor diversification in CD8+ T lymphocytes |
| Q37012718 | Rapid dissemination of RET-transgene-driven melanoma in the presence of non-obese diabetic alleles: Critical roles of Dectin-1 and Nitric-oxide synthase type 2. |
| Q44719693 | Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice |
| Q48186068 | Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses |
| Q35914938 | Regulation of immune responses by CD1d-restricted natural killer T cells |
| Q40096435 | Regulation of type 1 diabetes development and B-cell activation in nonobese diabetic mice by early life exposure to a diabetogenic environment. |
| Q34035323 | Restricted islet-cell reactive T cell repertoire of early pancreatic islet infiltrates in NOD mice |
| Q24674948 | Reversal of Sjogren's-like syndrome in non-obese diabetic mice |
| Q36369174 | Reversal of spontaneous autoimmune insulitis in nonobese diabetic mice by soluble lymphotoxin receptor |
| Q38242389 | Rodent animal models: from mild to advanced stages of diabetic nephropathy |
| Q36124501 | Role of regulatory invariant CD1d-restricted natural killer T-cells in protection against type 1 diabetes |
| Q40767304 | Selected contribution: Association of gender-related LMP2 inactivation with autoimmune pathogenesis |
| Q36609044 | Selective delivery of beta cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice. |
| Q54445458 | Specific gene expression signature associated with development of autoimmune type-I diabetes using whole-blood microarray analysis. |
| Q35923786 | Spontaneous rodent models of diabetes and diabetic retinopathy |
| Q27011453 | Stem cell therapy for diabetes mellitus |
| Q34391021 | Stem cell treatment for type 1 diabetes |
| Q53235135 | Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR). |
| Q92988627 | Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II |
| Q34734082 | Suppression of Th1-mediated autoimmunity by embryonic stem cell-derived dendritic cells |
| Q34629092 | Suppression of dendritic cell activation by diabetes autoantigens linked to the cholera toxin B subunit. |
| Q35597162 | T cell-driven initiation and propagation of autoimmune diabetes |
| Q35702538 | T-cell epitopes in type 1 diabetes |
| Q36943737 | Targeting CD22 reprograms B-cells and reverses autoimmune diabetes |
| Q54134699 | The CXCR4/CXCL12 (SDF-1) signalling pathway protects non-obese diabetic mouse from autoimmune diabetes. |
| Q47913426 | The Inhibitory G Protein α-Subunit, Gαz, Promotes Type 1 Diabetes-Like Pathophysiology in NOD Mice. |
| Q48364565 | The Journal of Gene Medicine 2001 Young Investigator Award |
| Q90345025 | The Role of Gut Microbiota and Environmental Factors in Type 1 Diabetes Pathogenesis |
| Q55024614 | The Spleen as an Optimal Site for Islet Transplantation and a Source of Mesenchymal Stem Cells. |
| Q90350445 | The challenge of modulating β-cell autoimmunity in type 1 diabetes |
| Q37759033 | The immunotherapeutic potential of dendritic cells in type 1 diabetes |
| Q27026794 | The microbiology of human hygiene and its impact on type 1 diabetes |
| Q36367836 | The natural killer T lymphocyte: a player in the complex regulation of autoimmune diabetes in non-obese diabetic mice |
| Q37160327 | The novel inosine analogue, INO-2002, protects against diabetes development in multiple low-dose streptozotocin and non-obese diabetic mouse models of type I diabetes |
| Q34496850 | The pancreas in human type 1 diabetes |
| Q35832523 | The pathogenesis of diabetes in the NOD mouse |
| Q38110933 | The potential role of dendritic cells in the therapy of Type 1 diabetes |
| Q57623514 | The problems and promises of research into human immunology and autoimmune disease |
| Q35103993 | The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure |
| Q38213215 | The role of Toll-like receptors and vitamin D in diabetes mellitus type 1--a review |
| Q36079915 | The stages of type 1A diabetes: 2005. |
| Q27023064 | The streetlight effect in type 1 diabetes |
| Q35867877 | Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells |
| Q34612686 | Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone. |
| Q36637650 | Thioreductase-Containing Epitopes Inhibit the Development of Type 1 Diabetes in the NOD Mouse Model |
| Q35613139 | Tolerance induction and endogenous regeneration of pancreatic beta-cells in established autoimmune diabetes |
| Q34359584 | Toward testing the hypothesis that group B coxsackieviruses (CVB) trigger insulin-dependent diabetes: inoculating nonobese diabetic mice with CVB markedly lowers diabetes incidence. |
| Q28530266 | Towards a medically approved technology for alginate-based microcapsules allowing long-term immunoisolated transplantation |
| Q43780207 | Treatment with sulfatide or its precursor, galactosylceramide, prevents diabetes in NOD mice |
| Q35837580 | Type 1 Diabetes Prevention in NOD Mice by Targeting DPPIV/CD26 Is Associated with Changes in CD8⁺T Effector Memory Subset |
| Q35714822 | Type 1 diabetes: recent developments |
| Q27320835 | Ultrasonic Stimulation of Mouse Skin Reverses the Healing Delays in Diabetes and Aging by Activation of Rac1. |
| Q34498188 | Understanding autoimmune diabetes: insights from mouse models. |
| Q46964184 | Unexpected functional consequences of xenogeneic transgene expression in beta-cells of NOD mice |
| Q34078163 | Use of nonobese diabetic mice to understand human type 1 diabetes |
| Q36898677 | Variations in rodent models of type 1 diabetes: islet morphology |
| Q34581550 | Viral infections as potential triggers of type 1 diabetes |
| Q37429158 | Virus-induced autoimmune diabetes in the LEW.1WR1 rat requires Iddm14 and a genetic locus proximal to the major histocompatibility complex |
| Q35042163 | Vitamin D and autoimmune diabetes |
| Q35878811 | What can the HLA transgenic mouse tell us about autoimmune diabetes? |
| Q51362614 | Zinc supplementation alleviates hyperglycemia and associated metabolic abnormalities in streptozotocin-induced diabetic rats. |
| Q92217601 | β Cell Hypoxia-Inducible Factor-1α Is Required for the Prevention of Type 1 Diabetes |
| Q38730525 | β-cell-specific IL-35 therapy suppresses ongoing autoimmune diabetes in NOD mice |